Novo CEO pressed by Senate to cut prices of obesity, diabetes drugs CEO Lars Fruergaard Jørgensen explained to lawmakers the business would take into account new talks with insurers regarding the record costs of Wegovy and copyright whenever they pledge to keep the medicines on their own formularies. Never skip https://felixdummh.blogdiloz.com/29948256/about-healthcare-news